LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Home・Aandelen Lijst・Cogent Biosciences Inc

Cogent Biosciences Inc

Gesloten

35.68 5.31

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

37.06

Belangrijke statistieken
By Trading Economics
Inkomsten	-22M -102M
EPS	-0.5
Werknemers	258
EBITDA	-30M -109M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+54.56% upside

Dividenden
By Dow Jones
Volgende Winsten	5 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	399M 6B
Vorige openingsprijs	30.37
Vorige sluitingsprijs	35.68

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

4.88 / 5.87 Steun & Weerstand

Cogent Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 mrt 2026, 21:37 UTC

Acquisities, Fusies, Overnames

Lensar and Alcon Agree to Terminate Merger

16 mrt 2026, 19:06 UTC

Belangrijke Nieuwsgebeurtenissen

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

16 mrt 2026, 17:44 UTC

Acquisities, Fusies, Overnames

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

16 mrt 2026, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

16 mrt 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise After Oil Prices Decline -- Market Talk

16 mrt 2026, 23:37 UTC

Marktinformatie

Gold Edges Higher on Possible Technical Recovery -- Market Talk

16 mrt 2026, 23:05 UTC

Marktinformatie

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

16 mrt 2026, 21:56 UTC

Marktinformatie

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

16 mrt 2026, 21:41 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

16 mrt 2026, 21:41 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

16 mrt 2026, 20:59 UTC

Acquisities, Fusies, Overnames

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

16 mrt 2026, 20:59 UTC

Acquisities, Fusies, Overnames

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

16 mrt 2026, 20:59 UTC

Acquisities, Fusies, Overnames

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

16 mrt 2026, 20:57 UTC

Acquisities, Fusies, Overnames

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

16 mrt 2026, 20:51 UTC

Acquisities, Fusies, Overnames

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

16 mrt 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

16 mrt 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Energy & Utilities Roundup: Market Talk

16 mrt 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

16 mrt 2026, 19:53 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

16 mrt 2026, 19:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

16 mrt 2026, 19:43 UTC

Marktinformatie

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

16 mrt 2026, 19:37 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Natural Gas Follows Oil Prices Lower -- Market Talk

16 mrt 2026, 19:20 UTC

Belangrijke Nieuwsgebeurtenissen

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

16 mrt 2026, 19:17 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

16 mrt 2026, 19:00 UTC

Marktinformatie

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

16 mrt 2026, 18:23 UTC

Marktinformatie

LME Restarts Trading After Outage -- Market Talk

16 mrt 2026, 17:36 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

16 mrt 2026, 17:19 UTC

Marktinformatie

Grains Sink as Investors Steer Toward Equities -- Market Talk

16 mrt 2026, 17:14 UTC

Belangrijke Nieuwsgebeurtenissen

Trump Ends News Conference

Peer Vergelijking

Prijswijziging

Cogent Biosciences Inc Prognose

Koersdoel

By TipRanks

54.56% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 52.55 USD 54.56%

Hoogste 64 USD

Laagste 35 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cogent Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Cogent Biosciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

4.88 / 5.87Steun & Weerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.